Qian D, et al. - In patients with type 2 diabetes uncontrolled on metformin, researchers tested the safety as well as the efficacy of oral antidiabetic drugs (OADs) as an add-on treatment via a search of PubMed, the Cochrane Library, and Embase from inception to October 20, 2017. For this investigation, 68 trials including 36,746 patients were analyzed. When combined with metformin, the seven classes of OADs were not related to an increased risk of major adverse cardiovascular events (MACEs) or all-cause mortality. They found that most OADs were correlated with similarly large decreases in glycated hemoglobin (HbA1c) levels when added to metformin. Results of this study suggested that sodium-glucose co-transporter-2 (SGLT-2) inhibitors might be the best option for reducing body weight, fasting plasma glucose (FPG), and 2 h postprandial glucose (2 h PPG).